On January 4, 2022 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, reported Jim Caruso, president and CEO and Jarrod Longcor, CBO, will participate in a fireside chat at the H.C. Wainwright Bioconnect conference taking place virtually January 10-13, 2022 (Press release, Cellectar Biosciences, JAN 4, 2022, https://investor.cellectar.com/news/detail/282/cellectar-to-participate-in-fireside-chat-at-the-h-c-wainwright-bioconnect-conference [SID1234598058]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The fireside chat will be available on demand beginning at 7:00 am ET on January 10, 2022. To access and view the event, investors are encouraged to register by clicking on this registration link.
The event also will be available on the News & Media section of the company’s website.